Osteoporosis Indication Strategy Report 2026: RANKL, Sclerostin, Trials and 46 Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Hypoparathyroidism Indication Strategy Report 2026: PTH1R, CaSR, Phase 3 Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Congenital Adrenal Hyperplasia Indication Strategy Report 2026: CYP21A2, CRHR1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Acromegaly Indication Strategy Report 2026: GHR, SSTR2, Trials and $1B Deal Signal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Cushing Syndrome Indication Strategy Report 2026: CYP11B1, GR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Primary Hyperaldosteronism Indication Strategy Report 2026: CYP11B2, MR, Trials and $1.8B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Portal Hypertension Indication Strategy Report 2026: sGC, ROCK2, Trials and Market Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Cirrhosis Indication Strategy Report 2026: TGF-β1, FXR, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Alcohol-Associated Hepatitis Indication Strategy Report 2026: IL-1β, TNF and Phase 3 Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

MASLD Indication Strategy Report 2026: THR-β, FGF21, Trials and $4.4B Deal Signal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Gout Indication Strategy Report 2026: Xanthine Oxidase, NLRP3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Primary Hyperoxaluria Indication Strategy Report 2026: GOX, LDHA, Gene Editing and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.